NTRK1 and colorectal carcinoma: Several clinical trials, such as the LOXO-TRK-14001, SCOUT, and NAVIGATE, have taken place to explore the potential benefit of a TRK inhibitor like larotrectinib in patients with NTRK fusion-positive tumors, including those with CRC [37,38,39].